HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cost-effectiveness of ximelagatran for stroke prevention.

AuthorsChristine Perret-Guillaume, Denis Wahl
JournalJAMA (JAMA) Vol. 293 Issue 23 Pg. 2860-1; author reply 2861 (Jun 15 2005) ISSN: 1538-3598 [Electronic] United States
PMID15956626 (Publication Type: Comment, Letter)
Chemical References
  • Anticoagulants
  • Azetidines
  • Benzylamines
  • Prodrugs
  • ximelagatran
  • Warfarin
Topics
  • Anticoagulants (economics, therapeutic use)
  • Atrial Fibrillation (complications, drug therapy, economics)
  • Azetidines (economics, therapeutic use)
  • Benzylamines
  • Cost-Benefit Analysis
  • Humans
  • Prodrugs (economics, therapeutic use)
  • Quality-Adjusted Life Years
  • Stroke (economics, etiology, prevention & control)
  • Warfarin (economics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: